Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2025
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gufic Biosciences has filed copies of the newspaper advertisement of its Q1 FY26 unaudited financial results with BSE and NSE, as required under SEBI (LODR) Regulation 47. The results, approved by the Board on August 13, 2025, were published in Business Standard (English) and Mumbai Lakshadeep (Marathi) on August 14, 2025. On a standalone basis, total income rose to ₹514.33 crore from ₹408.75 crore YoY, and net profit swung to ₹22.02 crore from a loss of ₹5.28 crore in the year-ago quarter (basic EPS of ₹5.50 vs. ₹(1.32)). On a consolidated basis, total income grew to ₹465.20 crore from ₹337.88 crore, with net profit at ₹6.32 crore compared to a loss of ₹41.67 crore YoY (EPS of ₹1.53 vs. ₹(10.37)). The detailed results are also available on the company's website and the stock exchange portals.
This is a routine regulatory newspaper-publication filing, not a fresh corporate action, so no immediate stock-moving effect is expected. However, the strong YoY turnaround from loss to profit on both standalone and consolidated bases is a positive signal for shareholders on underlying Q1 performance.